Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
WeightWatchers Rebrands to Capitalize on GLP-1 Popularity - Featured image
Health & Wellness

WeightWatchers Rebrands to Capitalize on GLP-1 Popularity

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·December 17, 2025·3 min read

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

WeightWatchers is undergoing a brand refresh to better integrate GLP-1 medications into its offerings. This shift comes after the company's bankruptcy filing, which cited the rapidly evolving weight management landscape. The rebrand includes new programs and features designed to support members using these medications.

Share

WeightWatchers Rebrands to Capitalize on GLP-1 Popularity

The growing popularity of GLP-1 medications is reshaping the health and wellness sector, potentially offering a crucial boost for WeightWatchers, which filed for bankruptcy last May. The company's bankruptcy announcement highlighted the "rapidly evolving weight management landscape" as a key focus area in its turnaround strategy.

WeightWatchers has previously incorporated GLP-1 options and promoted them in advertisements. However, this comprehensive overhaul positions the booming drug category as a more central and integrated element of its brand identity and business strategy. According to a press release, these changes were inspired by member feedback and are intended to reflect both the brand's 60-year history and a push toward modernization. These adjustments come before the new year, a period when many consumers establish personal fitness objectives, and as the GLP-1 market is projected to exceed $150 billion by 2030, fueled by the success of drugs like Ozempic, Zepbound, and Wegovy. Health tracking apps like Shotlee can help monitor progress and side effects when using such medications.

Julie Rice, chief experience officer at WeightWatchers, stated that this evolution extends beyond a new visual identity. She emphasized that the WeightWatchers brand is embodied in how they present themselves daily through their experience, coaches, community, and medical support. She added that everything is designed around a deep understanding of members' lives and goals, ensuring support feels personal, connected, and consistent across all WeightWatchers interactions.

The identity refresh was led by Mrs&Mr, appointed as WeightWatchers' global brand agency in September. Before bankruptcy and the departure of Oprah as a board member, WeightWatchers had appointed Ogilvy as its global creative agency. Ogilvy's initial campaign, "Fit You," showcased customer testimonials for WeightWatchers' clinical program.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

WeightWatchers has undergone several brand evolutions, including a 2018 rebrand to WW to signal a broader focus on wellness. The most recent update modifies the company's logo, replacing two stacked white Ws within a blue circle with a pair of separated letters bisected by a straight line symbolizing the weight-loss journey. Marketing materials showcase the updated look on various items, such as slippers, socks, and caps, complemented by a rich blue color scheme.

Beyond marketing, WeightWatchers is introducing several new features for its members. These include a dedicated GLP-1 program called Med+, which offers personalized nutrition guidance, medication dose tracking, support for managing drug side effects, and strategies for preserving muscle mass. Additionally, the WeightWatchers digital experience has been updated with an AI body scanner, a new Weight Health Score metric, and premium in-app fitness content for strength and functional movement training.

WeightWatchers has also diversified beyond its traditional focus on points-based weight-loss plans. In September, they launched their first dedicated menopause care program, with Queen Latifah as the celebrity spokesperson.

WeightWatchers, also known as WW International, reported a 10.8% year-over-year decline in total revenues, reaching $172 million for the Q3 period ending Sept. 30, representing their first full quarter post-restructuring. However, revenue from clinical subscriptions showed a positive trend, increasing by 35.3% year-over-year to $26 million.

Source Information

Originally published by Marketing Dive.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
Endocrinology

Semaglutide and Tirzepatide: The Reality of Stopping and Restarting

A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.

7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
Men's Health

Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?

A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.

7 min read
Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior
Health & Wellness

Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior

Groundbreaking research indicates that GLP-1 receptor agonists, widely recognized for their impact on diabetes and weight management, may also play a crucial role in modulating impulsive behaviors that can lead to criminal acts and violence.

6 min read

Same topic: Weight Management

All Weight Management articles →
Beyond the Hype: Navigating the Rise of Online Peptides
Health & Wellness

Beyond the Hype: Navigating the Rise of Online Peptides

A surge in injectable peptides marketed online for enhancement purposes is outpacing regulatory oversight, creating a 'grey zone' with potential public health implications. This article delves into the complexities, risks, and what consumers should understand.

6 min read
Beyond the Scale: GLP-1 Users & the Exercise Paradox
Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read
Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks
Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read

More in Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read
Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read
Share this article
  1. Home
  2. Blog
  3. WeightWatchers Rebrands to Capitalize on GLP-1 Popularity
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community